Health · Healthcare & Policy · 1 hr ago
Seven Indian children to receive free treatment for rare genetic disorder
Seven children in India with Allan-Herndon-Dudley syndrome are set to receive free treatment with the medicine tiratricol.
The rare genetic condition, also called MCT8 deficiency, affects how thyroid hormones reach brain cells.
The commercial medicine can cost ₹4.68 crore to ₹9 crore per child each year, placing it beyond the reach of most families.
A Hyderabad paediatrician, Dr. Sivaranjani Santosh, and Access to Medicines India helped arrange a compounded version prepared by a pharmacy in the Netherlands.
That version is estimated to cost ₹2.5 lakh per child for a year, and funding has been raised to provide treatment free to all seven children.
The first supply is due to be handed to families on November 30, with individual import permissions secured for one year of treatment.
Because the medicine lasts six months, it will be imported in two batches.
Seven children in India with Allan-Herndon-Dudley syndrome are set to receive a year’s supply of tiratricol free of charge on November 30.
The treatment is being provided through an initiative led by Hyderabad paediatrician Dr. Sivaranjani Santosh and Access to Medicines India.
A compounded formulation is estimated to cost ₹2.5 lakh per child for a year, compared with about ₹4.68 crore to ₹9 crore for the commercial version.
Transvaal Pharmacy in The Hague prepared the medicine with support from the Netherlands-based Pharmaceutical Accountability Foundation.
The medicine will be imported in two batches because the compounded formulation has a shelf life of six months.
- Who
- Seven children in India diagnosed with Allan-Herndon-Dudley syndrome will receive treatment.
- What
- They will receive a year’s supply of tiratricol free of charge.
- When
- The first batch is due to be handed over on November 30.
- Where
- The children are in India; the medicine was prepared by Transvaal Pharmacy in The Hague, Netherlands.
- Why
- The initiative aims to make treatment affordable for families who could not afford the commercial drug.
This story does not have two clearly opposing sides.
Dr. Sivaranjani Santosh posted an appeal on social media seeking help for a family.
The Pharmaceutical Accountability Foundation explored preparing the medicine through pharmaceutical compounding.
Transvaal Pharmacy conducted test batches and developed a formulation for the seven children.
The first batch is due to be handed over to the children’s parents.
- Children receiving treatment
- 7
- Condition
- Allan-Herndon-Dudley syndrome (AHDS), also known as MCT8 deficiency
- Medicine
- Tiratricol, also known as TRIAC
- Estimated compounded treatment cost
- ₹2.5 lakh per child for one year
- Commercial treatment cost
- Approximately ₹4.68 crore to ₹9 crore per child annually
- Total cost for all seven children
- €14,200, approximately ₹15.08 lakh